Aclarion Announces Statistically Significant Nociscan Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually.

The International Society for the Advancement of Spine Surgery (ISASS) Annual Meeting was held June 1-3, 2023.

ISASS Policy Statement on Lumbar Spinal Fusion Surgery acknowledges MR Spectroscopy as an effective alternative to provocative discography.

BROOMFIELD, CO, June 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their Nociscan cost-effectiveness abstract was presented at the International Society for the Advancement of Spine Surgery on Saturday, June 3, 2023.  The cost-effectiveness study comparing Nociscan to provocative discography was performed at the Center for Disruptive Musculoskeletal Innovations (CDMI) through a National Science Foundation (NSF) grant sponsored by Aclarion.  The abstract highlights that Nociscan statistically dominates provocative discography (PD) because PD is both more costly and less effective.

"An evidence-based process for accurate identification of a source for low back pain is valuable to improve cost-effectiveness of operative and non-operative management strategies," said Leslie Wilson, PhD, Professor in the Department of Medicine and the Department of Clinical Pharmacy at University of California San Francisco. “The economic model includes a decision-tree comparing Nociscan with PD based on a comprehensive set of peer-reviewed data. The incremental cost-effectiveness ratio (ICER) confirms that Nociscan statistically dominates PD, with a Monte Carlo sensitivity analysis illustrating Nociscan dominates over a wide willingness-to-pay range. In total, Nociscan can save the US healthcare system from $283M to $441M annually.”

Chronic low back pain (cLBP) is a global healthcare problem, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Conventional imaging and diagnostics provide valuable structural information but struggle to identify the source of the pathogenic pain. Low surgical success rates (41-57%)^1,2 are common especially for patients suffering from Discogenic Chronic Low Back Pain (DCLP).